TrialThe oncologist2020

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

Ghassan K Abou-Alfa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.